PPARG and heart failure: In recent years, synthetic PPARγ partial agonists [27,33,45,46] have emerged as a promising alternative to full agonists, demonstrating hypoglycemic efficacy while mitigating the risk of severe side effects commonly associated with full agonists, including weight gain, fluid retention and heart failure.